drugset / Trial / NCT06885840
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, phase II clinical study of MCLA-129 as monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with actionable gene alterations and MET amplification to evaluate the efficacy, safety, pharmacokinetic characteristics of MCLA-129.
Timeline
- Start
- 2025-03-31
- Primary completion
- 2028-04
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PAMVATAMIG | Monoclonal antibody | — | Intravenous |